|
Roger S, Pelegrin P, Surprenant A. Facilitation of P2X7 receptor currents and membrane blebbing via constitutive and dynamic calmodulin binding. J Neurosci. 2008 Jun 18;28(25):6393-401. doi: 10.1523/JNEUROSCI.0696-08.2008. PubMed PMID: 18562610.
AÑO: 2008; IF: 7.452
|
18562610
|
Pelegrin P. Targeting interleukin-1 signaling in chronic inflammation: focus on P2X(7) receptor and Pannexin-1. Drug News Perspect. 2008 Oct;21(8):424-33. doi: 10.1358/dnp.2008.21.8.1265800. Review. PubMed PMID: 19034348.
AÑO: 2008; IF: 1.989
|
|
Young MT, Pelegrin P, Surprenant A. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2007 Jan;71(1):92-100. Epub 2006 Oct 10. PubMed PMID: 17032903.
AÑO: 2007; IF: 3.622
|
|
Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem. 2007 Jan 26;282(4):2386-94. Epub 2006 Nov 22. PubMed PMID: 17121814.
AÑO: 2007; IF: 5.581
|
|
Young MT, Pelegrin P, Surprenant A. Identification of Thr283 as a key determinant of P2X7 receptor function. Br J Pharmacol. 2006 Oct;149(3):261-8. Epub 2006 Aug 29. PubMed PMID: 16940988; PubMed Central PMCID: PMC2014266.
AÑO: 2006; IF: 3.825
|